dc.contributor.author | Senkal, Zeynep | |
dc.contributor.author | Cakir, Sibel | |
dc.date.accessioned | 2021-03-03T11:02:02Z | |
dc.date.available | 2021-03-03T11:02:02Z | |
dc.identifier.citation | Cakir S., Senkal Z., "Atypical antipsychotics as add-on treatment in late-life depression", CLINICAL INTERVENTIONS IN AGING, cilt.11, ss.1193-1198, 2016 | |
dc.identifier.issn | 1178-1998 | |
dc.identifier.other | av_25bec358-9855-43cb-ba07-638cdce19033 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/30260 | |
dc.identifier.uri | https://doi.org/10.2147/cia.s114244 | |
dc.description.abstract | Background: Second-generation antipsychotics (SGAs) have been used in the augmentation of treatment-resistant depression. However, little is known about their effectiveness, tolerability, and adverse events in the treatment of late-life depression, which were the aim of this study. | |
dc.language.iso | eng | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Geriatri | |
dc.subject | GERİATRİK VE GERONTOLOJİ | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.title | Atypical antipsychotics as add-on treatment in late-life depression | |
dc.type | Makale | |
dc.relation.journal | CLINICAL INTERVENTIONS IN AGING | |
dc.contributor.department | Marmara Üniversitesi , , | |
dc.identifier.volume | 11 | |
dc.identifier.startpage | 1193 | |
dc.identifier.endpage | 1198 | |
dc.contributor.firstauthorID | 227827 | |